$BIOLQ
BIOLASE, INC

2024 Q4 Form 10-Q Financial Statement

#000095017024123472 Filed on November 07, 2024

View on sec.gov

Income Statement

Concept 2024 Q4 2024 Q3
Revenue $10.85M
YoY Change -0.65%
Cost Of Revenue $6.468M
YoY Change -9.85%
Gross Profit $4.382M
YoY Change 16.98%
Gross Profit Margin 40.39%
Selling, General & Admin $4.160M
YoY Change -31.59%
% of Gross Profit 94.93%
Research & Development $917.0K
YoY Change -32.67%
% of Gross Profit 20.93%
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $5.077M
YoY Change -31.79%
Operating Profit -$695.0K
YoY Change -81.2%
Interest Expense -$605.0K
YoY Change 1.17%
% of Operating Profit
Other Income/Expense, Net -$721.0K
YoY Change -17.79%
Pretax Income -$1.416M
YoY Change -69.04%
Income Tax $12.00K
% Of Pretax Income
Net Earnings -$1.428M
YoY Change -68.88%
Net Earnings / Revenue -13.16%
Basic Earnings Per Share -$0.04
Diluted Earnings Per Share -$0.04
COMMON SHARES
Basic Shares Outstanding 36.60M 36.60M
Diluted Shares Outstanding 36.08M

Balance Sheet

Concept 2024 Q4 2024 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments
YoY Change
Cash & Equivalents $3.400M
Short-Term Investments
Other Short-Term Assets
YoY Change
Inventory $9.870M
Prepaid Expenses
Receivables $3.500M
Other Receivables
Total Short-Term Assets $19.43M
YoY Change -30.07%
LONG-TERM ASSETS
Property, Plant & Equipment $3.658M
YoY Change -39.53%
Goodwill $2.900M
YoY Change 0.0%
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $260.0K
YoY Change -3.7%
Total Long-Term Assets $7.813M
YoY Change -28.73%
TOTAL ASSETS
Total Short-Term Assets $19.43M
Total Long-Term Assets $7.813M
Total Assets $27.24M
YoY Change -29.69%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $3.001M
YoY Change -58.19%
Accrued Expenses $8.153M
YoY Change 7.09%
Deferred Revenue $2.226M
YoY Change 1.6%
Short-Term Debt
YoY Change
Long-Term Debt Due $16.04M
YoY Change 472.93%
Total Short-Term Liabilities $30.86M
YoY Change 56.0%
LONG-TERM LIABILITIES
Long-Term Debt $0.00
YoY Change -100.0%
Other Long-Term Liabilities $106.0K
YoY Change 35.9%
Total Long-Term Liabilities $106.0K
YoY Change -99.07%
TOTAL LIABILITIES
Total Short-Term Liabilities $30.86M
Total Long-Term Liabilities $106.0K
Total Liabilities $32.12M
YoY Change -2.25%
SHAREHOLDERS EQUITY
Retained Earnings -$327.5M
YoY Change 5.15%
Common Stock $322.8M
YoY Change 3.29%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$5.227M
YoY Change
Total Liabilities & Shareholders Equity $27.24M
YoY Change -29.69%

Cashflow Statement

Concept 2024 Q4 2024 Q3
OPERATING ACTIVITIES
Net Income -$1.428M
YoY Change -68.88%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities
YoY Change
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities
YoY Change
NET CHANGE
Cash From Operating Activities
Cash From Investing Activities
Cash From Financing Activities
Net Change In Cash
YoY Change
FREE CASH FLOW
Cash From Operating Activities
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
14000
CY2023Q3 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
332000
us-gaap Profit Loss
ProfitLoss
-10711000
us-gaap Profit Loss
ProfitLoss
-15306000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
1955000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
2133000
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
216000
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
60000
biol Inventory Excess And Obsolescence
InventoryExcessAndObsolescence
76000
biol Inventory Excess And Obsolescence
InventoryExcessAndObsolescence
0
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
359000
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
320000
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-1060000
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-104000
biol Expiration Of Warrant Liabilities
ExpirationOfWarrantLiabilities
-548000
biol Expiration Of Warrant Liabilities
ExpirationOfWarrantLiabilities
0
us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
830000
us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
447000
us-gaap Share Based Compensation
ShareBasedCompensation
118000
us-gaap Share Based Compensation
ShareBasedCompensation
1050000
us-gaap Gain Loss On Sale Of Other Assets
GainLossOnSaleOfOtherAssets
286000
us-gaap Gain Loss On Sale Of Other Assets
GainLossOnSaleOfOtherAssets
0
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-1738000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-1393000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-1397000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
720000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
646000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-1322000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-4319000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-2301000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-263000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-102000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-11144000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-11808000
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Entity Central Index Key
EntityCentralIndexKey
0000811240
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2024-09-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-36385
dei Entity Registrant Name
EntityRegistrantName
BIOLASE, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
87-0442441
dei Entity Address Address Line1
EntityAddressAddressLine1
27042 Towne Centre Drive
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 270
dei Entity Address City Or Town
EntityAddressCityOrTown
Lake Forest
dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
92610
dei City Area Code
CityAreaCode
949
dei Local Phone Number
LocalPhoneNumber
361-1200
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2024Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
36597334
CY2024Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
3444000
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
6566000
CY2024Q3 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
457000
CY2023Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
244000
CY2024Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
3530000
CY2023Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
5483000
CY2024Q3 us-gaap Inventory Net
InventoryNet
9870000
CY2023Q4 us-gaap Inventory Net
InventoryNet
11433000
CY2024Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2584000
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1381000
CY2024Q3 us-gaap Assets Current
AssetsCurrent
19428000
CY2023Q4 us-gaap Assets Current
AssetsCurrent
24863000
CY2024Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3658000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
5525000
CY2024Q3 us-gaap Goodwill
Goodwill
2926000
CY2023Q4 us-gaap Goodwill
Goodwill
2926000
CY2024Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
969000
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1519000
CY2024Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
260000
CY2023Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
268000
CY2024Q3 us-gaap Assets
Assets
27241000
CY2023Q4 us-gaap Assets
Assets
35101000
CY2024Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
3001000
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
6065000
CY2024Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
8153000
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
7518000
CY2024Q3 biol Stock Warrant Liability
StockWarrantLiability
1437000
CY2023Q4 biol Stock Warrant Liability
StockWarrantLiability
1363000
CY2024Q3 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
2226000
CY2023Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
2452000
CY2024Q3 us-gaap Mediumterm Notes Current
MediumtermNotesCurrent
16042000
CY2023Q4 us-gaap Mediumterm Notes Current
MediumtermNotesCurrent
2265000
CY2024Q3 us-gaap Liabilities Current
LiabilitiesCurrent
30859000
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
19663000
CY2024Q3 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
220000
CY2023Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
256000
CY2024Q3 us-gaap Product Warranty Accrual Noncurrent
ProductWarrantyAccrualNoncurrent
726000
CY2023Q4 us-gaap Product Warranty Accrual Noncurrent
ProductWarrantyAccrualNoncurrent
593000
CY2024Q3 us-gaap Mediumterm Notes Noncurrent
MediumtermNotesNoncurrent
0
CY2023Q4 us-gaap Mediumterm Notes Noncurrent
MediumtermNotesNoncurrent
11782000
CY2024Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
211000
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
772000
CY2024Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
106000
CY2023Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
79000
CY2024Q3 us-gaap Liabilities
Liabilities
32122000
CY2023Q4 us-gaap Liabilities
Liabilities
33145000
CY2024Q3 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
346000
CY2023Q4 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
2203000
CY2024Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2024Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
180000000
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
180000000
CY2024Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
36597000
CY2024Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
36597000
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
3416000
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
3416000
CY2024Q3 us-gaap Common Stock Value
CommonStockValue
36000
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
3000
CY2024Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
322778000
CY2023Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
317103000
CY2024Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-530000
CY2023Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-553000
CY2024Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-327511000
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-316800000
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
-5227000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
-247000
CY2024Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
27241000
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
35101000
CY2024Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
10850000
CY2023Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
10921000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
32536000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
35674000
CY2024Q3 us-gaap Cost Of Revenue
CostOfRevenue
6468000
CY2023Q3 us-gaap Cost Of Revenue
CostOfRevenue
7175000
us-gaap Cost Of Revenue
CostOfRevenue
20209000
us-gaap Cost Of Revenue
CostOfRevenue
22474000
CY2024Q3 us-gaap Gross Profit
GrossProfit
4382000
CY2023Q3 us-gaap Gross Profit
GrossProfit
3746000
us-gaap Gross Profit
GrossProfit
12327000
us-gaap Gross Profit
GrossProfit
13200000
CY2024Q3 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
2877000
CY2023Q3 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
3402000
us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
9954000
us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
14214000
CY2024Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1283000
CY2023Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2679000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
7544000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
7495000
CY2024Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
917000
CY2023Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1362000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3271000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
4352000
CY2024Q3 us-gaap Operating Expenses
OperatingExpenses
5077000
CY2023Q3 us-gaap Operating Expenses
OperatingExpenses
7443000
us-gaap Operating Expenses
OperatingExpenses
20769000
us-gaap Operating Expenses
OperatingExpenses
26061000
CY2024Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-695000
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-3697000
us-gaap Operating Income Loss
OperatingIncomeLoss
-8442000
us-gaap Operating Income Loss
OperatingIncomeLoss
-12861000
CY2024Q3 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-69000
CY2023Q3 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-307000
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-278000
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-522000
CY2024Q3 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-605000
CY2023Q3 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-598000
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-1812000
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-1758000
CY2024Q3 us-gaap Other Income
OtherIncome
-47000
CY2023Q3 us-gaap Other Income
OtherIncome
28000
us-gaap Other Income
OtherIncome
-128000
us-gaap Other Income
OtherIncome
-119000
CY2024Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-721000
CY2023Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-877000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-2218000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-2399000
CY2024Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-1416000
CY2023Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-4574000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-10660000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-15260000
CY2024Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
12000
CY2023Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
15000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
51000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
46000
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-1428000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-4589000
us-gaap Net Income Loss
NetIncomeLoss
-10711000
us-gaap Net Income Loss
NetIncomeLoss
-15306000
CY2024Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
129000
CY2023Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-105000
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
23000
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
14000
CY2024Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-1299000
CY2023Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-4694000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-10688000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-15292000
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-1428000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-4589000
us-gaap Net Income Loss
NetIncomeLoss
-10711000
us-gaap Net Income Loss
NetIncomeLoss
-15306000
CY2024Q3 biol Deemed Dividend On Convertible Preferred Stock
DeemedDividendOnConvertiblePreferredStock
-71000
CY2023Q3 biol Deemed Dividend On Convertible Preferred Stock
DeemedDividendOnConvertiblePreferredStock
7610000
biol Deemed Dividend On Convertible Preferred Stock
DeemedDividendOnConvertiblePreferredStock
-71000
biol Deemed Dividend On Convertible Preferred Stock
DeemedDividendOnConvertiblePreferredStock
16987000
CY2024Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-1357000
CY2023Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-12199000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-10640000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-32293000
CY2024Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.04
CY2024Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.04
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-10.35
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-10.35
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.37
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.37
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-47.01
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-47.01
CY2024Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
36083000
CY2024Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
36083000
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1179000
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1179000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
29131000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
29131000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
687000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
687000
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
-4329000
CY2024Q3 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
-10000
CY2024Q3 biol Stock Issued During Period Preferred Stock Warrants Exchanged Value
StockIssuedDuringPeriodPreferredStockWarrantsExchangedValue
360000
CY2024Q3 biol Stock Issued During Period Preferred Stock Warrants Expired Value
StockIssuedDuringPeriodPreferredStockWarrantsExpiredValue
1000
CY2024Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
50000
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-1428000
CY2024Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
129000
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
-5227000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
-247000
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
2775000
biol Stock Issued During Period Value Class A Warrants Exercised
StockIssuedDuringPeriodValueClassAWarrantsExercised
1989000
us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
528000
biol Stockissuedduringperiodpreferredstockwarrantsexercisedvalue
Stockissuedduringperiodpreferredstockwarrantsexercisedvalue
-164000
biol Stock Issued During Period Preferred Stock Warrants Exchanged Value
StockIssuedDuringPeriodPreferredStockWarrantsExchangedValue
360000
biol Stock Issued During Period Preferred Stock Warrants Expired Value
StockIssuedDuringPeriodPreferredStockWarrantsExpiredValue
1000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
210000
biol Stock Issued During Period Value Common Stock Warrants Exercised
StockIssuedDuringPeriodValueCommonStockWarrantsExercised
9000
us-gaap Net Income Loss
NetIncomeLoss
-10711000
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
23000
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
-5227000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
6621000
CY2023Q3 us-gaap Stock And Warrants Issued During Period Value Preferred Stock And Warrants
StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants
7611000
CY2023Q3 biol Stockissuedduringperiodpreferredstockwarrantsexercisedvalue
Stockissuedduringperiodpreferredstockwarrantsexercisedvalue
-148000
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
224000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-4589000
CY2023Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-105000
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
332000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
4889000
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
8503000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1149000
biol Stock Issued During Period Value Common Stock Warrants Exercised
StockIssuedDuringPeriodValueCommonStockWarrantsExercised
114000
us-gaap Net Income Loss
NetIncomeLoss
-15306000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
67000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1126000
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
358000
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
0
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
291000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-1126000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
2776000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
8503000
biol Proceeds From The Sale Of Series H Convertible Preferred Stock Net Of Fees
ProceedsFromTheSaleOfSeriesHConvertiblePreferredStockNetOfFees
0
biol Proceeds From The Sale Of Series H Convertible Preferred Stock Net Of Fees
ProceedsFromTheSaleOfSeriesHConvertiblePreferredStockNetOfFees
5490000
biol Proceeds From Sale Of Common Stock Warrants
ProceedsFromSaleOfCommonStockWarrants
3020000
biol Proceeds From Sale Of Common Stock Warrants
ProceedsFromSaleOfCommonStockWarrants
1743000
biol Borrowings Under Term Loan
BorrowingsUnderTermLoan
-2500000
biol Borrowings Under Term Loan
BorrowingsUnderTermLoan
0
biol Principal Payment On Term Loan
PrincipalPaymentOnTermLoan
865000
biol Principal Payment On Term Loan
PrincipalPaymentOnTermLoan
0
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
8000
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
114000
us-gaap Proceeds From Issuance Of Preferred Stock Preference Stock And Warrants
ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants
270000
us-gaap Proceeds From Issuance Of Preferred Stock Preference Stock And Warrants
ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants
699000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
7709000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
16549000
biol Effect Of Exchange Rate Changes
EffectOfExchangeRateChanges
22000
biol Effect Of Exchange Rate Changes
EffectOfExchangeRateChanges
13000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-3122000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
3628000
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
6566000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
4181000
CY2024Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
3444000
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
7809000
us-gaap Interest Paid Net
InterestPaidNet
970000
us-gaap Interest Paid Net
InterestPaidNet
1419000
us-gaap Proceeds From Interest Received
ProceedsFromInterestReceived
5000
us-gaap Proceeds From Interest Received
ProceedsFromInterestReceived
7000
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
53000
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
12000
biol Cash Paid For Operating Leases
CashPaidForOperatingLeases
238000
biol Cash Paid For Operating Leases
CashPaidForOperatingLeases
230000
biol Non Cash Property Plant And Equipment Additions Acquired Under Inventory
NonCashPropertyPlantAndEquipmentAdditionsAcquiredUnderInventory
110000
biol Non Cash Property Plant And Equipment Additions Acquired Under Inventory
NonCashPropertyPlantAndEquipmentAdditionsAcquiredUnderInventory
0
biol Common Stock Issued Upon Cashless Warrant Exercise
CommonStockIssuedUponCashlessWarrantExercise
1989000
biol Common Stock Issued Upon Cashless Warrant Exercise
CommonStockIssuedUponCashlessWarrantExercise
0
biol Common Stock Issued Upon Exercise Of Preferred Stock
CommonStockIssuedUponExerciseOfPreferredStock
528000
biol Common Stock Issued Upon Exercise Of Preferred Stock
CommonStockIssuedUponExerciseOfPreferredStock
18503000
biol Common Stock Issued Upon Exchange Of Preferred Share And Preferred Share Warrants
CommonStockIssuedUponExchangeOfPreferredShareAndPreferredShareWarrants
360000
biol Common Stock Issued Upon Exchange Of Preferred Share And Preferred Share Warrants
CommonStockIssuedUponExchangeOfPreferredShareAndPreferredShareWarrants
0
biol Liability For Settlment Of Preferred Shares
LiabilityForSettlmentOfPreferredShares
1581000
biol Liability For Settlment Of Preferred Shares
LiabilityForSettlmentOfPreferredShares
0
biol Non Cash Right Of Use Assets Obtained In Exchange For Lease Obligation
NonCashRightOfUseAssetsObtainedInExchangeForLeaseObligation
78000
biol Non Cash Right Of Use Assets Obtained In Exchange For Lease Obligation
NonCashRightOfUseAssetsObtainedInExchangeForLeaseObligation
483000
biol Maturity Date
MaturityDate
-120
CY2024Q3 biol Working Capital
WorkingCapital
11400000
CY2024Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
3400000
CY2024Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
3500000
CY2023Q4 biol Working Capital
WorkingCapital
5200000
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
6600000
CY2023Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
5500000
us-gaap Use Of Estimates
UseOfEstimates
<p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Use of Estimates</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The preparation of these condensed consolidated financial statements in conformity with GAAP requires the Company to make estimates and assumptions that affect amounts reported in the condensed consolidated financial statements and the accompanying notes. Significant estimates in these condensed consolidated financial statements include allowances on accounts receivable, inventory, and deferred taxes, as well as estimates for accrued warranty expenses, goodwill and the ability of goodwill to be realized, revenue deferrals, effects of stock-based compensation and warrants, contingent liabilities, the provision or benefit for income taxes, and preferred stock. Due to the inherent uncertainty involved in making estimates, actual results reported in future periods may differ materially from those estimates.</span></p>
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Concentration of Credit Risk, Interest Rate Risk and Foreign Currency Exchange Rate</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Financial instruments which potentially expose the Company to a concentration of credit risk consist principally of cash and cash equivalents, and trade accounts receivable. The Company maintains its cash and cash equivalents with established commercial banks. At times, balances may exceed federally insured limits. To minimize the risk associated with trade accounts receivable, management performs ongoing credit evaluations of customers’ financial condition and maintains relationships with the Company’s customers that allow management to monitor current changes in business operations so the Company can respond as needed. The Company does not, generally, require customers to provide collateral before it sells them its products. However, the Company has required certain distributors to make prepayments for significant purchases of its products.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Substantially all of the Company’s revenue is denominated in U.S. dollars, including sales to international distributors. Only a small portion of its revenue and expenses is denominated in foreign currencies, principally the Euro and Indian Rupee. The Company’s foreign currency expenditures primarily consist of the cost of maintaining offices, consulting services, and employee-related costs. During the three and nine months ended September 30, 2024 and 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, respectively, the Company did not enter into any hedging contracts. Future fluctuations in the value of the U.S. dollar may affect the price competitiveness of the Company’s products outside the U.S.</span></p>
CY2024Q3 biol Revenue From Products And Services Transferred To Customers Percentage
RevenueFromProductsAndServicesTransferredToCustomersPercentage
0.88
biol Revenue From Products And Services Transferred To Customers Percentage
RevenueFromProductsAndServicesTransferredToCustomersPercentage
0.86
CY2023Q3 biol Revenue From Products And Services Transferred To Customers Percentage
RevenueFromProductsAndServicesTransferredToCustomersPercentage
0.87
biol Revenue From Products And Services Transferred To Customers Percentage
RevenueFromProductsAndServicesTransferredToCustomersPercentage
0.89
CY2024Q3 biol Revenue From Services Transferred To Customers Over Time Percentage
RevenueFromServicesTransferredToCustomersOverTimePercentage
0.12
biol Revenue From Services Transferred To Customers Over Time Percentage
RevenueFromServicesTransferredToCustomersOverTimePercentage
0.14
CY2023Q3 biol Revenue From Services Transferred To Customers Over Time Percentage
RevenueFromServicesTransferredToCustomersOverTimePercentage
0.13
biol Revenue From Services Transferred To Customers Over Time Percentage
RevenueFromServicesTransferredToCustomersOverTimePercentage
0.11
CY2024Q3 biol Contract With Customer Liability In Undelivered Elements
ContractWithCustomerLiabilityInUndeliveredElements
500000
CY2023Q4 biol Contract With Customer Liability In Undelivered Elements
ContractWithCustomerLiabilityInUndeliveredElements
400000
CY2024Q3 biol Contract With Customer Liability In Undelivered Elements
ContractWithCustomerLiabilityInUndeliveredElements
511000
CY2023Q4 biol Contract With Customer Liability In Undelivered Elements
ContractWithCustomerLiabilityInUndeliveredElements
449000
CY2024Q3 biol Contract With Customer Liability In Extended Warranty Contracts
ContractWithCustomerLiabilityInExtendedWarrantyContracts
1935000
CY2023Q4 biol Contract With Customer Liability In Extended Warranty Contracts
ContractWithCustomerLiabilityInExtendedWarrantyContracts
2259000
CY2024Q3 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
2446000
CY2023Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
2708000
CY2024Q3 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
220000
CY2023Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
256000
CY2024Q3 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
2226000
CY2023Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
2452000
biol Contract With Customer Liability Revenue Recognized Undelivered Elements
ContractWithCustomerLiabilityRevenueRecognizedUndeliveredElements
400000
biol Contract With Customer Liability Revenue Recognized Undelivered Elements
ContractWithCustomerLiabilityRevenueRecognizedUndeliveredElements
300000
biol Contract With Customer Liability Revenue Recognized Extended Warranty
ContractWithCustomerLiabilityRevenueRecognizedExtendedWarranty
1800000
biol Contract With Customer Liability Revenue Recognized Extended Warranty
ContractWithCustomerLiabilityRevenueRecognizedExtendedWarranty
1500000
CY2024Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
10850000
CY2023Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
10921000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
32536000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
35674000
CY2024Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
10850000
CY2023Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
10921000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
32536000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
35674000
CY2024Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
10850000
CY2023Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
10921000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
32536000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
35674000
CY2024Q3 us-gaap Temporary Equity Shares Issued
TemporaryEquitySharesIssued
1000000
biol Allocated Share Based Compensation Expense Credit
AllocatedShareBasedCompensationExpenseCredit
100000
CY2024Q3 biol Allocated Share Based Compensation Expense Credit
AllocatedShareBasedCompensationExpenseCredit
100000
CY2023Q3 biol Allocated Share Based Compensation Expense Credit
AllocatedShareBasedCompensationExpenseCredit
300000
biol Allocated Share Based Compensation Expense Credit
AllocatedShareBasedCompensationExpenseCredit
1100000
CY2024Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
100000
CY2023Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
700000
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P1Y2M12D
CY2024Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
51000
CY2023Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
276000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
118000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1050000
CY2024Q1 us-gaap Fair Value Investments Entities That Calculate Net Asset Value Per Share Percent Equity Securities
FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerSharePercentEquitySecurities
0.95
CY2024Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
200000
biol Offering Of Common Stock
OfferingOfCommonStock
23010024
biol Offering Of Common Stock
OfferingOfCommonStock
2537031
CY2024Q3 us-gaap Inventory Raw Materials
InventoryRawMaterials
5028000
CY2023Q4 us-gaap Inventory Raw Materials
InventoryRawMaterials
6168000
CY2024Q3 us-gaap Inventory Work In Process
InventoryWorkInProcess
1262000
CY2023Q4 us-gaap Inventory Work In Process
InventoryWorkInProcess
1299000
CY2024Q3 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
3580000
CY2023Q4 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
3966000
CY2024Q3 us-gaap Inventory Net
InventoryNet
9870000
CY2023Q4 us-gaap Inventory Net
InventoryNet
11433000
CY2024Q3 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
2300000
CY2023Q4 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
2500000
CY2024Q3 biol Property Plant And Equipment Gross Excluding Land
PropertyPlantAndEquipmentGrossExcludingLand
14783000
CY2023Q4 biol Property Plant And Equipment Gross Excluding Land
PropertyPlantAndEquipmentGrossExcludingLand
16695000
CY2024Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
11287000
CY2023Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
11330000
CY2024Q3 biol Property Plant And Equipment Net Excluding Land
PropertyPlantAndEquipmentNetExcludingLand
3496000
CY2023Q4 biol Property Plant And Equipment Net Excluding Land
PropertyPlantAndEquipmentNetExcludingLand
5365000
CY2024Q3 us-gaap Land
Land
162000
CY2023Q4 us-gaap Land
Land
160000
CY2024Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3658000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
5525000
CY2024Q3 us-gaap Depreciation And Amortization
DepreciationAndAmortization
600000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
2000000
CY2023Q3 us-gaap Depreciation And Amortization
DepreciationAndAmortization
600000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
2100000
us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0
CY2024Q3 biol Discount Rate For Fair Value Level3
DiscountRateForFairValueLevel3
0.191
CY2024Q3 us-gaap Goodwill
Goodwill
2900000
CY2023Q4 us-gaap Goodwill
Goodwill
2900000
CY2024Q3 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
0
CY2023Q3 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
0
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
0
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
0
CY2024Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
2625000
CY2023Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
3343000
CY2024Q3 us-gaap Preferred Stock Redemption Amount Future Redeemable Securities
PreferredStockRedemptionAmountFutureRedeemableSecurities
1581000
CY2023Q4 us-gaap Preferred Stock Redemption Amount Future Redeemable Securities
PreferredStockRedemptionAmountFutureRedeemableSecurities
0
CY2024Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
856000
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
888000
CY2024Q3 us-gaap Product Warranty Accrual Classified Current
ProductWarrantyAccrualClassifiedCurrent
800000
CY2023Q4 us-gaap Product Warranty Accrual Classified Current
ProductWarrantyAccrualClassifiedCurrent
1321000
CY2024Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
778000
CY2023Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
422000
CY2024Q3 us-gaap Interest Payable Current
InterestPayableCurrent
723000
CY2023Q4 us-gaap Interest Payable Current
InterestPayableCurrent
256000
CY2024Q3 us-gaap Taxes Payable Current
TaxesPayableCurrent
386000
CY2023Q4 us-gaap Taxes Payable Current
TaxesPayableCurrent
452000
CY2024Q3 us-gaap Accrued Insurance Current
AccruedInsuranceCurrent
0
CY2023Q4 us-gaap Accrued Insurance Current
AccruedInsuranceCurrent
473000
CY2024Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
404000
CY2023Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
363000
CY2024Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
8153000
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
7518000
CY2024Q2 us-gaap Product Warranty Accrual
ProductWarrantyAccrual
1843000
CY2023Q2 us-gaap Product Warranty Accrual
ProductWarrantyAccrual
1772000
CY2023Q4 us-gaap Product Warranty Accrual
ProductWarrantyAccrual
1914000
CY2022Q4 us-gaap Product Warranty Accrual
ProductWarrantyAccrual
1653000
CY2024Q3 us-gaap Product Warranty Accrual Preexisting Increase Decrease
ProductWarrantyAccrualPreexistingIncreaseDecrease
346000
CY2023Q3 us-gaap Product Warranty Accrual Preexisting Increase Decrease
ProductWarrantyAccrualPreexistingIncreaseDecrease
997000
us-gaap Product Warranty Accrual Preexisting Increase Decrease
ProductWarrantyAccrualPreexistingIncreaseDecrease
1833000
us-gaap Product Warranty Accrual Preexisting Increase Decrease
ProductWarrantyAccrualPreexistingIncreaseDecrease
2957000
CY2024Q3 us-gaap Product Warranty Accrual Payments
ProductWarrantyAccrualPayments
663000
CY2023Q3 us-gaap Product Warranty Accrual Payments
ProductWarrantyAccrualPayments
942000
us-gaap Product Warranty Accrual Payments
ProductWarrantyAccrualPayments
2221000
us-gaap Product Warranty Accrual Payments
ProductWarrantyAccrualPayments
2783000
CY2024Q3 us-gaap Product Warranty Accrual
ProductWarrantyAccrual
1526000
CY2023Q3 us-gaap Product Warranty Accrual
ProductWarrantyAccrual
1827000
CY2024Q3 us-gaap Product Warranty Accrual
ProductWarrantyAccrual
1526000
CY2023Q3 us-gaap Product Warranty Accrual
ProductWarrantyAccrual
1827000
CY2024Q3 us-gaap Product Warranty Accrual Noncurrent
ProductWarrantyAccrualNoncurrent
726000
CY2023Q3 us-gaap Product Warranty Accrual Noncurrent
ProductWarrantyAccrualNoncurrent
463000
CY2024Q3 us-gaap Product Warranty Accrual Noncurrent
ProductWarrantyAccrualNoncurrent
726000
CY2023Q3 us-gaap Product Warranty Accrual Noncurrent
ProductWarrantyAccrualNoncurrent
463000
CY2024Q3 us-gaap Product Warranty Accrual Classified Current
ProductWarrantyAccrualClassifiedCurrent
800000
CY2023Q3 us-gaap Product Warranty Accrual Classified Current
ProductWarrantyAccrualClassifiedCurrent
1364000
CY2024Q3 us-gaap Product Warranty Accrual Classified Current
ProductWarrantyAccrualClassifiedCurrent
800000
CY2023Q3 us-gaap Product Warranty Accrual Classified Current
ProductWarrantyAccrualClassifiedCurrent
1364000
CY2024Q3 us-gaap Long Term Debt
LongTermDebt
16042000
CY2023Q4 us-gaap Long Term Debt
LongTermDebt
14047000
CY2024Q3 us-gaap Long Term Debt Current
LongTermDebtCurrent
16042000
CY2023Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
2265000
CY2024Q3 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
0
CY2023Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
11782000
CY2024Q3 us-gaap Interest Expense Debt
InterestExpenseDebt
600000
us-gaap Interest Expense Debt
InterestExpenseDebt
1800000
CY2023Q3 us-gaap Interest Expense Debt
InterestExpenseDebt
600000
us-gaap Interest Expense Debt
InterestExpenseDebt
1800000
CY2024Q3 us-gaap Debt Weighted Average Interest Rate
DebtWeightedAverageInterestRate
0.1455
CY2024Q3 us-gaap Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year
LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear
16345000
CY2024Q3 biol Long Term Debt Maturities Repayments Of Interest Remainder Of Fiscal Year
LongTermDebtMaturitiesRepaymentsOfInterestRemainderOfFiscalYear
2209000
CY2024Q3 us-gaap Long Term Debt Maturities Repayments Of Principal In Next Twelve Months
LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
0
CY2024Q3 biol Long Term Debt Maturities Repayments Of Interest In Next Twelve Months
LongTermDebtMaturitiesRepaymentsOfInterestInNextTwelveMonths
0
CY2024Q3 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Two
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
0
CY2024Q3 biol Long Term Debt Maturities Repayments Of Interest In Year Two
LongTermDebtMaturitiesRepaymentsOfInterestInYearTwo
0
CY2024Q3 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Three
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
0
CY2024Q3 biol Long Term Debt Maturities Repayments Of Interest In Year Three
LongTermDebtMaturitiesRepaymentsOfInterestInYearThree
0
CY2024Q3 biol Long Term Debt Maturities Repayments Of Principal After Year Four
LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFour
0
CY2024Q3 biol Long Term Debt Maturities Repayments Of Interest In Year After Four
LongTermDebtMaturitiesRepaymentsOfInterestInYearAfterFour
0
CY2024Q3 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
16345000
CY2024Q3 biol Long Term Debt Maturities Repayments Of Interest
LongTermDebtMaturitiesRepaymentsOfInterest
2209000
CY2024Q3 us-gaap Lessee Operating Lease Renewal Term
LesseeOperatingLeaseRenewalTerm
P1Y
us-gaap Lease Expiration Date1
LeaseExpirationDate1
2025-12-31
CY2020Q1 us-gaap Lessee Operating Lease Term Of Contract
LesseeOperatingLeaseTermOfContract
P5Y
CY2020Q1 biol Lease Facility Area
LeaseFacilityArea
11000
CY2020Q1 us-gaap Lease Expiration Date1
LeaseExpirationDate1
2020-07-01
CY2021Q4 biol Lease Facility Area
LeaseFacilityArea
15000
CY2024Q3 us-gaap Operating Lease Payments
OperatingLeasePayments
81000
CY2023Q3 us-gaap Operating Lease Payments
OperatingLeasePayments
70000
us-gaap Operating Lease Payments
OperatingLeasePayments
238000
us-gaap Operating Lease Payments
OperatingLeasePayments
230000
CY2024Q3 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
78000
CY2023Q3 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
0
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
78000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
483000
CY2024Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P1Y2M12D
CY2023Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P2Y
CY2024Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P1Y2M12D
CY2023Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P2Y
CY2024Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.146
CY2023Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.123
CY2024Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.146
CY2023Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.123
us-gaap Lessee Operating Lease Lease Not Yet Commenced Description
LesseeOperatingLeaseLeaseNotYetCommencedDescription
the Company had no significant leases that had not commenced.
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
904000
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
238000
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
9000
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
0
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Five
LesseeOperatingLeaseLiabilityPaymentsDueYearFive
0
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
1151000
CY2024Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
84000
CY2024Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
1067000
CY2024Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
856000
CY2024Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
211000
CY2024Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
1067000
CY2024Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1000000
CY2024Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
1100000
CY2024Q3 us-gaap Payments For Rent
PaymentsForRent
300000
us-gaap Payments For Rent
PaymentsForRent
900000
CY2023Q3 us-gaap Payments For Rent
PaymentsForRent
300000
us-gaap Payments For Rent
PaymentsForRent
900000
CY2024Q3 biol Future Minimum Payments Remainder Of Fiscal Year
FutureMinimumPaymentsRemainderOfFiscalYear
267000
CY2024Q3 biol Future Minimum Payments Due In One Year
FutureMinimumPaymentsDueInOneYear
849000
CY2024Q3 biol Future Minimum Payments Due In Two Years
FutureMinimumPaymentsDueInTwoYears
35000
CY2024Q3 biol Future Minimum Payments Due In Three Years
FutureMinimumPaymentsDueInThreeYears
0
CY2024Q3 biol Future Minimum Payments Due Thereafter
FutureMinimumPaymentsDueThereafter
0
CY2024Q3 biol Future Minimum Payments Due
FutureMinimumPaymentsDue
1151000
CY2024Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
84000
CY2024Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
1067000
CY2024Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
10850000
CY2023Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
10921000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
32536000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
35674000
CY2024Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3658000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
5525000
CY2024Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
10850000
CY2023Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
10921000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
32536000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
35674000
biol Unrecognized Tax Benefits Period Increases Decreases
UnrecognizedTaxBenefitsPeriodIncreasesDecreases
0
CY2024Q3 biol Unrecognized Tax Benefits Period Increases Decreases
UnrecognizedTaxBenefitsPeriodIncreasesDecreases
0
CY2023Q3 biol Unrecognized Tax Benefits Period Increases Decreases
UnrecognizedTaxBenefitsPeriodIncreasesDecreases
0
biol Unrecognized Tax Benefits Period Increases Decreases
UnrecognizedTaxBenefitsPeriodIncreasesDecreases
0
CY2024Q3 biol Income Tax Provision
IncomeTaxProvision
12000
biol Income Tax Provision
IncomeTaxProvision
51000
CY2024Q3 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.008
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.005
CY2023Q3 biol Income Tax Provision
IncomeTaxProvision
15000
biol Income Tax Provision
IncomeTaxProvision
46000
CY2023Q3 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.003
us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2024Q3 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2024Q3 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2024Q3 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false
CY2024Q3 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false

Files In Submission

Name View Source Status
0000950170-24-123472-index-headers.html Edgar Link pending
0000950170-24-123472-index.html Edgar Link pending
0000950170-24-123472.txt Edgar Link pending
0000950170-24-123472-xbrl.zip Edgar Link pending
biol-20240930.htm Edgar Link pending
biol-20240930.xsd Edgar Link pending
biol-ex31_1.htm Edgar Link pending
biol-ex31_2.htm Edgar Link pending
biol-ex32_1.htm Edgar Link pending
biol-ex32_2.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
biol-20240930_htm.xml Edgar Link completed
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending